Anhedonia as an indicator of genetic vulnerability to schizophrenia

Anhedonia: A Comprehensive Handbook Volume II: Neuropsychiatric and Physical Disorders

Volumn , Issue , 2014, Pages 105-123

  Docherty, Anna R ^a   Sponheim, Scott R ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anhedonia; Gene; Phenotype; Relatives; Schizophrenia

Indexed keywords

EID: 84923207632     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-017-8610-2_4     Document Type: Chapter

References (95)

1. Fanous AH, van den Oord EJ, Riley BP, et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry. 2005;162(10):1824-32.
2. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-53.
3. Kerns JG, Docherty AR, Martin EA. Social and physical anhedonia and valence and arousal aspects of emotional experience. J Abnorm Psychol. 2008;117(4):735-46.
4. Horan WP, Kring AM, Blanchard JJ. Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull. 2006;32:259-73.
5. Dworkin RH, Saczynski K. Individual differences in hedonic capacity. J Pers Assess. 1984;48:620-6.
6. Cohen AS, Minor KS. Emotional experience in patients with schizophrenia re-revisited: metaanalysis of laboratory studies. Schizophr Bull. 2010;36:143-50.
7. Maher B. Personal genomes: the case of the missing heritability. Nature. 2008;456(7218):18-21.
8. Fanous AH, Zhou B, Aggen SH, et al. Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. Am J Psychiatry. 2012;169(12):1309-17.
9. Kendler KS, Diehl SR. The genetics of schizophrenia: a current, genetic epidemiological perspective. Schizophr Bull. 1993;19(2):261-85.
10. Faraone SV, Seidman LJ, Kremen WS, et al. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. J Abnorm Psychol. 1995;104(2):286-304.
11. Lawrie SM, Whalley H, Kestelman JN, et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet. 1999;353(9146):30-3.
12. McDonald C, Grech A, Toulopoulou T, et al. Brain volumes in familial and non-familial schizophrenic probands and their unaffected relatives. Am J Med Genet. 2002;114(6):616-25.
13. Byrne M, Clafferty BA, Cosway R, et al. Neuropsychology, genetic liability, and psychotic symptoms in those at high risk of schizophrenia. J Abnorm Psychol. 2003;112(1):38-48.
14. McIntosh AM, Harrison LK, Forrester K, et al. Neuropsychological impairments in people with schizophrenia or bipolar disorder and their unaffected relatives. Br J Psychiatry. 2005;186:378-85.
15. McIntosh AM, Job DE, Moorhead TW, et al. White matter density in patients with schizophrenia, bipolar disorder and their unaffected relatives. Biol Psychiatry. 2005;58(3):254-7.
16. Rado S. Psychoanalysis of behavior: collected papers. New York: Grune & Stratton; 1956.
17. Rado S. Theory and therapy: the theory of schizotypal organization and its application to the treatment of decompensated schizotypal behavior. In: Scher SC, Davis HR, editors. The outpatient treatment of schizophrenia. New York: Grune & Stratton; 1960.
18. Rado S, Daniels G. Changing concepts of psychoanalytic medicine. New York: Grune & Stratton; 1956.
19. Meehl PE. Primary and secondary hypohedonia. J Abnorm Psychol. 2001;110(1):188-93.
20. Kendler KS, Neale MC. Endophenotype: a conceptual analysis. Mol Psychiatry. 2010;15(8):789-97.
21. Neale MC, Kendler KS. Models of comorbidity for multifactorial disorders. Am J Human Genet. 1995;57:935-53.
22. Kendler KS, Neale MC. Endophenotype: a conceptual analysis. Mol Psychiatry. 2010;15(8):789-97.
23. Miller G, Rockstroh B. Endophenotypes in psychopathology research: where do we stand? Annu Rev Clin Psychol. 2013;9:15.1-15.38.
24. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636-45.
25. Lenzenweger MF. Thinking clearly about the endophenotype - intermediate phenotype - biomarker distinctions in developmental psychopathology research. Dev Psychopathol. 2013;25:1347-1357.
26. Cannon TD, Keller MC. Endophenotypes in the genetic analyses of mental disorders. Annu Rev Clin Psychol. 2006;2:267-90.
27. Katsanis J, Iacono WG, Beiser M. Anhedonia and perceptual aberration in first-episode psychotic patients and their relatives. J Abnorm Psychol. 1990;99(2):202-6.
28. Kendler KS, Ochs AL, Gorman AM, et al. The structure of schizotypy: a pilot multitrait twin study. Psychiatry Res. 1991;36(1):19-36.
29. Dworkin RH, Lenzenweger MF. Symptoms and the genetics of schizophrenia: implications for diagnosis. Am J Psychiatry. 1984;141:1541-6.
30. Kendler KS, Thacker L, Walsh D. Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia. Schizophr Bull. 1996;22(3):511-20.
31. MacDonald 3rd AW, Pogue-Geile MF, Debski TT, et al. Genetic and environmental influences on schizotypy: a community-based twin study. Schizophr Bull. 2001;27(1):47-58.
32. Vollema MG, Sitskoorn MM, Appels MC, et al. Does the schizotypal personality questionnaire reflect the biological-genetic vulnerability to schizophrenia? Schizophr Res. 2002; 54(1-2):39-45.
33. Schurhoff F, Szoke A, Meary A, et al. Familial aggregation of delusional proneness in schizophrenia and bipolar pedigrees. Am J Psychiatry. 2003;160(7):1313-9.
34. Docherty AR, Sponheim SR. Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. J Abnorm Psychol. 2008;117(4):788-98.
35. Kuha A, Suvisaari J, Perala J, et al. Associations of anhedonia and cognition in persons with schizophrenia spectrum disorders, their siblings, and controls. J Nerv Ment Dis. 2011;199(1):30-7.
36. Franke P, Maier W, Hardt J, et al. Cognitive functioning and anhedonia in subjects at risk for schizophrenia. Schizophr Res. 1993;10(1):77-84.
37. Clementz BA, Grove WM, Katsanis J, et al. Psychometric detection of schizotypy: perceptual aberration and physical anhedonia in relatives of schizophrenics. J Abnorm Psychol. 1991;100(4):607-12.
38. Etain B, Roy I, Henry C, et al. No evidence for physical anhedonia as a candidate symptom or an endophenotype in bipolar affective disorder. Bipolar Disord. 2007;9(7):706-12.
39. Catts SV, Fox AM, Ward PB, et al. Schizotypy: phenotypic marker as risk factor. Aust N Z J Psychiatry. 2000;34(Suppl):S101-7.
40. Glatt SJ, Stone WS, Faraone SV, et al. Psychopathology, personality traits and social development of young first-degree relatives of patients with schizophrenia. Br J Psychiatry. 2006;189:337-45.
41. Freedman LR, Rock D, Roberts SA, et al. The New York High-Risk Project: attention, anhedonia and social outcome. Schizophr Res. 1998;30(1):1-9.
42. Berenbaum H, McGrew J. Familial resemblance of schizotypic traits. Psychol Med. 1993;23(2):327-33.
43. Lyons MJ, Toomey R, Faraone SV, et al. Correlates of psychosis proneness in relatives of schizophrenic patients. J Abnorm Psychol. 1995;104(2):390-4.
44. Fanous A, Gardner C, Walsh D, et al. Relationship between positive and negative symptoms of schizophrenia and schizotypal symptoms in nonpsychotic relatives. Arch Gen Psychiatry. 2001;58(7):669-73.
45. Schurhoff F, Szoke A, Bellivier F, et al. Anhedonia in schizophrenia: a distinct familial subtype? Schizophr Res. 2003;61(1):59-66.
46. Seidman LJ, Kremen WS, Koren D, et al. A comparative profile analysis of neuropsychological functioning in patients with schizophrenia and bipolar psychoses. Schizophr Res. 2002;53(1-2):31-44.
47. Kamath V, Moberg PJ, Kohler CG, et al. Odor hedonic capacity and anhedonia in schizophrenia and unaffected first-degree relatives of schizophrenia patients. Schizophr Bull. 2013;39(1):59-67.
48. Chapman LJ, Chapman JP, Kwapil TR, et al. Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol. 1994;103(2):171-83.
49. Kwapil TR. Social anhedonia as a predictor of the development of schizophrenia-spectrum disorders. J Abnorm Psychol. 1998;107(4):558-65.
50. Gooding DC, Tallent KA, Matts CW. Clinical status of at-risk individuals 5 years later: further validation of the psychometric high-risk strategy. J Abnorm Psychol. 2005;114(1):170-5.
51. Kerns JG. Schizotypy facets, cognitive control, and emotion. J Abnorm Psychol. 2006;115(3):418-27.
52. Cicero DC, Becker TM, Martin EA, et al. The role of aberrant salience and self-concept clarity in psychotic-like experiences. Personal Disord. 2013;4(1):33-42.
53. Dillon DG, Bogdan R, Fagerness J, et al. Variation in TREK1 gene linked to depressionresistant phenotype is associated with potentiated neural responses to rewards in humans. Hum Brain Mapp. 2010;31(2):210-21.
54. Grant P, Kuepper Y, Mueller EA, et al. Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE)-a suitable endophenotype of schizophrenia. Front Hum Neurosci. 2013;7:1.
55. Chien YL, Hwu HG, Fann CS, et al. DRD2 haplotype associated with negative symptoms and sustained attention deficits in Han Chinese with schizophrenia in Taiwan. J Hum Genet. 2013;58(4):229-32.
56. Hikida T, Jaaro-Peled H, Seshadri S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A. 2007;104(36):14501-6.
57. Meyer KD, Morris JA. Disc1 regulates granule cell migration in the developing hippocampus. Hum Mol Genet. 2009;18(17):3286-97.
58. Kumari V, Mitterschiffthaler MT, Teasdale JD, et al. Neural abnormalities during cognitive generation of affect in treatment-resistant depression. Biol Psychiatry. 2003;54(8):777-91.
59. Szendi I, Kiss M, Racsmany M, et al. Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. Psychiatry Res. 2006;147(1):47-55.
60. Bilder RM, Volavka J, Lachman HM, et al. The catechol-O-methyltransferase polymorphism:relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29(11):1943-61.
61. Hong J, Shu-Leong H, Tao X, et al. Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport. 1998;9(12):2861-4.
62. Tan HY, Callicott JH, Weinberger DR. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn Neuropsychiatry. 2009;14(4-5):277-98.
63. Prata DP, Mechelli A, Fu CH, et al. Epistasis between the DAT 3′ UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc Natl Acad Sci U S A. 2009;106(32):13600-5.
64. Depue RA, Collins PF. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci. 1999;22(3):491-517.
65. Salamone JD, Correa M, Farrar A, et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl). 2007;191(3):461-82.
66. Li WJ, Kou CG, Yu Y, et al. Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(4):370-5.
67. O’Tuathaigh CM, Kirby BP, Moran PM, et al. Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr Bull. 2010;36(2):271-88.
68. Le Pen G, Gaudet L, Mortas P, et al. Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berl). 2002;161(4):434-41.
69. Moreau JL, Borgulya J, Jenck F, et al. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol. 1994;5(3):344-50.
70. Dreher JC, Kohn P, Berman KF. Neural coding of distinct statistical properties of reward information in humans. Cereb Cortex. 2006;16(4):561-73.
71. Rolls ET. The affective and cognitive processing of touch, oral texture, and temperature in the brain. Neurosci Biobehav Rev. 2010;34(2):237-45.
72. Tomppo L, Hennah W, Miettunen J, et al. Association of variants in DISC1 with psychosisrelated traits in a large population cohort. Arch Gen Psychiatry. 2009;66(2):134-41.
73. Tomppo L, Ekelund J, Lichtermann D, et al. DISC1 conditioned GWAS for psychosis proneness in a large Finnish birth cohort. PLoS One. 2012;7(2):e30643.
74. Bader V, Tomppo L, Trossbach SV, et al. Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits. Hum Mol Genet. 2012;21(20):4406-18.
75. Avramopoulos D, Stefanis NC, Hantoumi I, et al. Higher scores of self reported schizotypy in healthy young males carrying the COMT high activity allele. Mol Psychiatry. 2002;7(7):706-11.
76. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull. 1991;17(4):555-64.
77. Stefanis NC, Van Os J, Avramopoulos D, et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol Psychiatry. 2004;56(7):510-5.
78. Schurhoff F, Szoke A, Chevalier F, et al. Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(1):64-8.
79. Ceaser A, Csernansky JG, Barch DM. COMT influences on prefrontal and striatal blood oxygenation level-dependent responses during working memory among individuals with schizophrenia, their siblings, and healthy controls. Cogn Neuropsychiatry. 2013; 18(4):257-83.
80. Ashby FG, Isen AM, Turken AU. A neuropsychological theory of positive affect and its influence on cognition. Psychol Rev. 1999;106(3):529-50.
81. Levinson DF, Mowry BJ, Escamilla MA, et al. The Lifetime Dimensions of Psychosis Scale (LDPS): description and interrater reliability. Schizophr Bull. 2002;28(4):683-95.
82. Chen WJ, Hsiao CK, Lin CC. Schizotypy in community samples: the three-factor structure and correlation with sustained attention. J Abnorm Psychol. 1997;106(4):649-54.
83. Park S, McTigue K. Working memory and the syndromes of schizotypal personality. Schizophr Res. 1997;26(2-3):213-20.
84. Tarbox SI, Almasy L, Gur RE, et al. The nature of schizotypy among multigenerational multiplex schizophrenia families. J Abnorm Psychol. 2012;121(2):396-406.
85. Eaton NR, Krueger RF, Docherty AR, et al. Toward a model-based approach to the clinical assessment of personality psychopathology. J Pers Assess. 2013;1-10.
86. Urosevic S, Abramson LY, Harmon-Jones E, et al. Dysregulation of the behavioral approach system (BAS) in bipolar spectrum disorders: review of theory and evidence. Clin Psychol Rev. 2008;28(7):1188-205.
87. Robinson MD, Clore GL. Belief and feeling: evidence for an accessibility model of emotional self-report. Psychol Bull. 2002;128(6):934-60.
88. Docherty AR. A unifying hypothesis for the pathogenesis of schizotypal anhedonia. 2010. Schizophrenia Research Forum, www.schizophreniaforum.org/images/SRFSIRSEssaytop12. pdf. Accessed 21 Aug 2013.
89. Docherty AR, Cicero DC, Becker TM, et al. Self-reported ambivalence in schizophrenia and associations with negative mood. J Nerv Ment Dis, in press.
90. Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry. 2012;169(4):364-73.
91. Strauss GP. The emotion paradox of anhedonia in schizophrenia: or is it? Schizophr Bull. 2013;39(2):247-50.
92. Dowd EC, Barch DM. Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia. PLoS One. 2012;7(5):e35622.
93. Gold JM, Strauss GP, Waltz JA, et al. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry. 2013;74(2):130-6.
94. Gold JM, Waltz JA, Matveeva TM, et al. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch Gen Psychiatry. 2012;69(2):129-38.
95. Lenzenweger MF. Schizotypy and Schizophrenia: the view from experimental psychopathology. New York: Guilford Press; 2010.